Barriers and Opportunities for CAR T-Cell Targeting of Solid Tumors

References

• Adusumilli PS, Zauderer MG, Riviere I, Solomon SB, Rusch VW, O’Cearbhaill RE, Zhu A, Cheema W, Chintala NK, Halton E, et al. 2021. A phase I trial of regional mesothelin-targeted CAR T-cell therapy in patients with malignant pleural disease, in combination with the Anti–PD-1 agent Pembrolizumab. Cancer Discov. 11(11):2748–63.
   PubMed Web of Science ®Google Scholar
• Avanzi MP, Yeku O, Li X, Wijewarnasuriya DP, van Leeuwen DG, Cheung K, Park H, Purdon TJ, Daniyan AF, Spitzer MH, et al. 2018. Engineered tumor-targeted T cells mediate enhanced anti-tumor efficacy both directly and through activation of the endogenous immune system. Cell Rep. 23(7):2130–41.
   PubMed Web of Science ®Google Scholar
• Barber A, Zhang T, DeMars LR, Conejo-Garcia J, Roby KF, Sentman CL. 2007. Chimeric NKG2D receptor-bearing T cells as immunotherapy for ovarian cancer. Cancer Res. 67(10):5003–08.
   PubMed Web of Science ®Google Scholar
• Cadilha BL, Benmebarek MR, Dorman K, Oner A, Lorenzini T, Obeck H, Vanttinen M, Di Pilato M, Pruessmann JN, Stoiber S, et al. 2021. Combined tumor-directed recruitment and protection from immune suppression enable CAR T cell efficacy in solid tumors. Sci Adv. 7(24). doi:10.1126/sciadv.abi5781.
   PubMed Web of Science ®Google Scholar
• Cao Y, Trillo-Tinoco J, Sierra RA, Anadon C, Dai W, Mohamed E, Cen L, Costich TL, Magliocco A, Marchion D, et al. 2019. ER stress-induced mediator C/EBP homologous protein thwarts effector T cell activity in tumors through T-bet repression. Nat Commun. 10(1):1280.
   PubMedGoogle Scholar
• Ceelen W, Braet H, van Ramshorst G, Willaert W, Remaut K. 2020. Intraperitoneal chemotherapy for peritoneal metastases: an expert opinion. Expert Opin Drug Deliv. 17(4):511–22.
   PubMed Web of Science ®Google Scholar
• Curio S, Jonsson G, Marinovic S. 2021. A summary of current NKG2D-based CAR clinical trials. Immunother Adv. 1(1):ltab018.
   PubMedGoogle Scholar
• Di Marco Barros R, Roberts NA, Dart RJ, Vantourout P, Jandke A, Nussbaumer O, Deban L, Cipolat S, Hart R, Iannitto ML, et al. 2016. Epithelia use butyrophilin-like molecules to shape organ-specific gammadelta T cell compartments. Cell. 167(1):203–18 e17.
   PubMed Web of Science ®Google Scholar
• Du H, Hirabayashi K, Ahn S, Kren NP, Montgomery SA, Wang X, Tiruthani K, Mirlekar B, Michaud D, Greene K, et al. 2019. Antitumor responses in the absence of toxicity in solid tumors by targeting B7-H3 via chimeric antigen receptor T cells. Cancer Cell. 35(2):221–37 e8.
   PubMed Web of Science ®Google Scholar
• Fleming C, Morrissey S, Cai Y, Yan J. 2017. Gammadelta T cells: unexpected regulators of cancer development and progression. Trends Cancer. 3(8):561–70.
   PubMed Web of Science ®Google Scholar
• Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, Teachey DT, Chew A, Hauck B, Wright JF, et al. 2013. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 368(16):1509–18.
   PubMed Web of Science ®Google Scholar
• Heczey A, Courtney AN, Montalbano A, Robinson S, Liu K, Li M, Ghatwai N, Dakhova O, Liu B, Raveh-Sadka T, et al. 2020. Anti-GD2 CAR-NKT cells in patients with relapsed or refractory neuroblastoma: an interim analysis. Nat Med. 26(11):1686–90.
   PubMed Web of Science ®Google Scholar
• Hernandez-Lopez RA, Yu W, Cabral KA, Creasey OA, Lopez Pazmino MDP, Tonai Y, De Guzman A, Makela A, Saksela K, Gartner ZJ, et al. 2021. T cell circuits that sense antigen density with an ultrasensitive threshold. Science. 371(6534):1166–71.
   PubMed Web of Science ®Google Scholar
• Hirabayashi K, Du H, Xu Y, Shou P, Zhou X, Fuca G, Landoni E, Sun C, Chen Y, Savoldo B, et al. 2021. Dual targeting CAR-T cells with optimal costimulation and metabolic fitness enhance antitumor activity and prevent escape in solid tumors. Nat Cancer. 2(9):904–18.
   PubMedGoogle Scholar
• Keane JT, Posey AD, Jr. 2021. Chimeric antigen receptors expand the repertoire of antigenic macromolecules for cellular immunity. Cells. 10(12):3356.
   PubMed Web of Science ®Google Scholar
• Klichinsky M, Ruella M, Shestova O, Lu XM, Best A, Zeeman M, Schmierer M, Gabrusiewicz K, Anderson NR, Petty NE, et al. 2020. Human chimeric antigen receptor macrophages for cancer immunotherapy. Nat Biotechnol. 38(8):947–53.
   PubMed Web of Science ®Google Scholar
• Labanieh L, Majzner RG, Klysz D, Sotillo E, Fisher CJ, Vilches-Moure JG, Pacheco KZB, Malipatlolla M, Xu P, Hui JH, et al. 2022. Enhanced safety and efficacy of protease-regulated CAR-T cell receptors. Cell. 185(10):1745–63 e22.
   PubMed Web of Science ®Google Scholar
• Larson RC, Kann MC, Bailey SR, Haradhvala NJ, Llopis PM, Bouffard AA, Scarfo I, Leick MB, Grauwet K, Berger TR, et al. 2022. CAR T cell killing requires the IFNgammaR pathway in solid but not liquid tumours. Nature. 604(7906):563–70.
   PubMed Web of Science ®Google Scholar
• Liu E, Marin D, Banerjee P, Macapinlac HA, Thompson P, Basar R, Nassif Kerbauy L, Overman B, Thall P, Kaplan M, et al. 2020. Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors. N Engl J Med. 382(6):545–53.
   PubMed Web of Science ®Google Scholar
• Locke FL, Miklos DB, Jacobson CA, Perales MA, Kersten MJ, Oluwole OO, Ghobadi A, Rapoport AP, McGuirk J, Pagel JM, et al. 2022. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. N Engl J Med. 386(7):640–54.
   PubMed Web of Science ®Google Scholar
• Maggs L, Cattaneo G, Dal AE, Moghaddam AS, Ferrone S. 2021. CAR T cell-based immunotherapy for the treatment of glioblastoma. Front Neurosci. 15:15662064.
   Web of Science ®Google Scholar
• Majzner RG, Ramakrishna S, Yeom KW, Patel S, Chinnasamy H, Schultz LM, Richards RM, Jiang L, Barsan V, Mancusi R, et al. 2022. GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas. Nature. 603(7903):934–41.
   PubMed Web of Science ®Google Scholar
• Makkouk A, Yang XC, Barca T, Lucas A, Turkoz M, Wong JTS, Nishimoto KP, Brodey MM, Tabrizizad M, Gundurao SRY, et al. 2021. Off-The-Shelf Vδ1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma. J Immunother Cancer. 9(12):e003441.
   PubMed Web of Science ®Google Scholar
• Mansilla-Soto J, Eyquem J, Haubner S, Hamieh M, Feucht J, Paillon N, Zucchetti AE, Li Z, Sjostrand M, Lindenbergh PL, et al. 2022. HLA-Independent T cell receptors for targeting tumors with low antigen density. Nat Med. 28(2):345–52.
   PubMed Web of Science ®Google Scholar
• Martin AL, Anadon CM, Biswas S, Mine JA, Handley KF, Payne KK, Mandal G, Chaurio RA, Powers JJ, Sprenger KB, et al. 2022. Olfactory receptor OR2H1 is an effective target for CAR T cells in human epithelial tumors. Mol Cancer Ther. 21(7):1184–94.
   PubMed Web of Science ®Google Scholar
• Melenhorst JJ, Chen GM, Wang M, Porter DL, Chen C, Collins MA, Gao P, Bandyopadhyay S, Sun H, Zhao Z, et al. 2022. Decade-Long leukaemia remissions with persistence of CD4(+) CAR T cells. Nature. 602(7897):503–09.
   PubMed Web of Science ®Google Scholar
• Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA. 2010. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther. 18(4):843–51.
   PubMed Web of Science ®Google Scholar
• Murad JP, Kozlowska AK, Lee HJ, Ramamurthy M, Chang WC, Yazaki P, Colcher D, Shively J, Cristea M, Forman SJ, et al. 2018. Effective targeting of TAG72+ peritoneal ovarian tumors via regional delivery of CAR-engineered T cells. Front Immunol. 9:92268.
   Web of Science ®Google Scholar
• Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, Braunschweig I, Oluwole OO, Siddiqi T, Lin Y, et al. 2017. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 377(26):2531–44.
   PubMed Web of Science ®Google Scholar
• Neelapu SS, Dickinson M, Munoz J, Ulrickson ML, Thieblemont C, Oluwole OO, Herrera AF, Ujjani CS, Lin Y, Riedell PA, et al. 2022. Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial. Nat Med. 28(4):735–42.
   PubMed Web of Science ®Google Scholar
• O’Rourke DM, Nasrallah MP, Desai A, Melenhorst JJ, Mansfield K, Morrissette JJD, Martinez-Lage M, Brem S, Maloney E, Shen A, et al. 2017. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. Sci Transl Med. 9(399). doi:10.1126/scitranslmed.aaa0984.
   PubMed Web of Science ®Google Scholar
• Payne KK, Mine JA, Biswas S, Chaurio RA, Perales-Puchalt A, Anadon CM, Costich TL, Harro CM, Walrath J, Ming Q, et al. 2020. BTN3A1 governs antitumor responses by coordinating αβ and γδ T cells. Science. 369(6506):942–49.
   PubMed Web of Science ®Google Scholar
• Perales-Puchalt A, Svoronos N, Rutkowski MR, Allegrezza MJ, Tesone AJ, Payne KK, Wickramasinghe J, Nguyen JM, O’Brien SW, Gumireddy K, et al. 2017. Follicle-stimulating hormone receptor is expressed by most ovarian cancer subtypes and is a safe and effective immunotherapeutic target. Clin Cancer Res. 23(2):441–53.
   PubMed Web of Science ®Google Scholar
• Porter DL, Levine BL, Kalos M, Bagg A, June CH. 2011. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med. 365(8):725–33.
   PubMed Web of Science ®Google Scholar
• Raje N, Berdeja J, Lin Y, Siegel D, Jagannath S, Madduri D, Liedtke M, Rosenblatt J, Maus MV, Turka A, et al. 2019. Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. N Engl J Med. 380(18):1726–37.
   PubMed Web of Science ®Google Scholar
• Ryan SO, Vlad AM, Islam K, Gariepy J, Finn OJ. 2009. Tumor-Associated MUC1 glycopeptide epitopes are not subject to self-tolerance and improve responses to MUC1 peptide epitopes in MUC1 transgenic mice. Biol Chem. 390(7):611–18.
   PubMed Web of Science ®Google Scholar
• Song M, Sandoval TA, Chae CS, Chopra S, Tan C, Rutkowski MR, Raundhal M, Chaurio RA, Payne KK, Konrad C, et al. 2018. Ire1alpha-XBP1 controls T cell function in ovarian cancer by regulating mitochondrial activity. Nature. 562(7727):423–28.
   PubMed Web of Science ®Google Scholar
• Stadtmauer EA, Fraietta JA, Davis MM, Cohen AD, Weber KL, Lancaster E, Mangan PA, Kulikovskaya I, Gupta M, Chen F, et al. 2020. CRISPR-Engineered T cells in patients with refractory cancer. Science. 367(6481). doi:10.1126/science.aba7365.
   PubMed Web of Science ®Google Scholar
• Suzuki T, Hayman L, Kilbey A, Edwards J, Coffelt SB. 2020. Gut gammadelta T cells as guardians, disruptors, and instigators of cancer. Immunol Rev. 298(1):198–217.
   PubMed Web of Science ®Google Scholar
• Watanabe K, Terakura S, Martens AC, van Meerten T, Uchiyama S, Imai M, Sakemura R, Goto T, Hanajiri R, Imahashi N, et al. 2015. Target antigen density governs the efficacy of anti-CD20-CD28-CD3 zeta chimeric antigen receptor-modified effector CD8+ T cells. J Immunol. 194(3):911–20.
   PubMed Web of Science ®Google Scholar
• Wu Y, Biswas D, Usaite I, Angelova M, Boeing S, Karasaki T, Veeriah S, Czyzewska-Khan J, Morton C, Joseph M, et al. 2022. A local human Vδ1 T cell population is associated with survival in nonsmall-cell lung cancer. Nat Cancer. 3(6):696–709.
   PubMedGoogle Scholar
• Yeku OO, Purdon TJ, Koneru M, Spriggs D, Brentjens RJ. 2017. Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment. Sci Rep. 7(1):10541.
   PubMedGoogle Scholar
• Zakeri N, Hall A, Swadling L, Pallett LJ, Schmidt NM, Diniz MO, Kucykowicz S, Amin OE, Gander A, Pinzani M, et al. 2022. Characterisation and induction of tissue-resident gamma delta T-cells to target hepatocellular carcinoma. Nat Commun. 13(1):1372.
   PubMed Web of Science ®Google Scholar
• Zhang H, Yu P, Tomar VS, Chen X, Atherton MJ, Lu Z, Zhang HG, Li S, Ortiz A, Gui J, et al. 2022. Targeting PARP11 to avert immunosuppression and improve CAR T therapy in solid tumors. Nat Cancer. doi:10.1038/s43018-022-00383-0.
   Google Scholar